rs112571971
Variant summary
Our verdict is Benign. Variant got -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBS1BS2
The NM_001195263.2(PDZD7):c.1613G>A(p.Gly538Glu) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00675 in 1,549,712 control chromosomes in the GnomAD database, including 63 homozygotes. In-silico tool predicts a benign outcome for this variant. 9/12 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★).
Frequency
Consequence
NM_001195263.2 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -20 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
PDZD7 | NM_001195263.2 | c.1613G>A | p.Gly538Glu | missense_variant | 11/17 | ENST00000619208.6 | NP_001182192.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
PDZD7 | ENST00000619208.6 | c.1613G>A | p.Gly538Glu | missense_variant | 11/17 | 5 | NM_001195263.2 | ENSP00000480489 | P1 | |
PDZD7 | ENST00000644782.1 | c.1522+2327G>A | intron_variant | ENSP00000496747 | ||||||
PDZD7 | ENST00000474125.7 | c.*1700+2327G>A | intron_variant, NMD_transcript_variant | 2 | ENSP00000474447 |
Frequencies
GnomAD3 genomes AF: 0.00661 AC: 1006AN: 152146Hom.: 9 Cov.: 32
GnomAD3 exomes AF: 0.00695 AC: 1018AN: 146564Hom.: 7 AF XY: 0.00692 AC XY: 547AN XY: 79058
GnomAD4 exome AF: 0.00676 AC: 9447AN: 1397448Hom.: 54 Cov.: 34 AF XY: 0.00658 AC XY: 4535AN XY: 689254
GnomAD4 genome AF: 0.00661 AC: 1006AN: 152264Hom.: 9 Cov.: 32 AF XY: 0.00727 AC XY: 541AN XY: 74454
ClinVar
Submissions by phenotype
not provided Benign:5
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 29, 2024 | - - |
Benign, criteria provided, single submitter | clinical testing | Athena Diagnostics | Jul 18, 2019 | - - |
Benign, criteria provided, single submitter | clinical testing | GeneDx | Feb 22, 2019 | - - |
Likely benign, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Jul 01, 2024 | PDZD7: BP4, BS2 - |
Likely benign, criteria provided, single submitter | not provided | Breakthrough Genomics, Breakthrough Genomics | - | - - |
not specified Benign:2
Likely benign, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Feb 05, 2013 | Gly538Glu in Exon 11 of PDZD7: This variant is not expected to have clinical sig nificance because it has been identified in 1.6% (3/186) of Finnish individuals from a broad population by the 1000 Genomes Project (rs112571971). - |
Likely benign, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Sep 28, 2015 | - - |
PDZD7-related disorder Benign:1
Benign, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Nov 18, 2019 | This variant is classified as benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at